Convatec Unveils Next-Gen Wound Care Arsenal at Major European Summit

BREMEN, GERMANY – May 05, 2026 – As the global healthcare community grapples with the mounting crisis of chronic wounds, medical technology firm Convatec is positioning itself at the forefront of a paradigm shift. The company is set to dominate the conversation at the European Wound Management Association (EWMA) 2026 conference this week, showcasing a formidable pipeline of advanced wound care innovations backed by a wealth of new clinical data.

With 13 scientific abstracts accepted for presentation and five recently launched or approved products taking center stage, Convatec is signaling a strategic, aggressive push to move beyond incremental improvements in a field desperate for breakthroughs. The company's presence in Bremen is less a product update and more a declaration of intent to reshape the future of healing for millions of patients worldwide suffering from debilitating conditions like diabetic foot ulcers and venous leg ulcers.

The Science of Healing: Nitric Oxide and Placental Tech

Headlining Convatec's innovation showcase are two particularly groundbreaking technologies that venture into the realm of biologics and advanced chemistry. The first, ConvaNiox™, is a transformative dressing that generates nitric oxide (NO), a molecule critical to the body's natural healing and immune responses.

Nitric oxide's production is often impaired in patients with diabetes, hindering their ability to fight infection and close wounds. By delivering NO directly to the wound bed, ConvaNiox aims to overcome this deficit. The results presented are compelling: clinical data demonstrates the technology helps heal 60% more diabetic foot ulcers (DFUs) and achieves a wound area reduction three times faster compared to standard-of-care dressings. This multimodal approach harnesses NO's potent antimicrobial and antibiofilm properties, addressing a key barrier to healing in chronic wounds. While experts view the technology as a significant step forward, they also note the need for more long-term outcome data to fully assess its impact.

Equally innovative is ConvaMatrix™, a recently approved wound matrix derived from porcine placenta. This advanced biomaterial acts as a natural scaffold, leveraging the structural and biological components of the placenta's extracellular matrix (ECM) to support the body's own healing processes. Placental-derived materials have been studied for over a century for their rich composition of growth factors and cytokines that promote cell migration and tissue regeneration. Independent analyses have confirmed that such therapies can significantly increase the rate of complete ulcer healing in chronic DFUs compared to standard care. By offering this technology in a reproducible and safety-profiled medical device, Convatec is aiming to make a complex biological solution more accessible for treating persistent DFUs and venous leg ulcers (VLUs).

A Multi-Pronged Attack on Hard-to-Heal Wounds

Beyond these flagship innovations, Convatec is demonstrating the breadth of its portfolio, reinforcing its foundational technologies while pushing them into new territory. The EWMA conference also marks the 30th anniversary of the company's proprietary Hydrofiber® technology, a cornerstone of its wound care platform that has been used in nearly 1.5 billion dressings worldwide.

Building on this legacy, the company is introducing Aquacel™ ConvaFiber™, a next-generation version of its soft, conformable primary dressing. It boasts 45% more absorbency than its predecessor, a critical factor in managing the heavy exudate common in chronic wounds. This is complemented by ConvaFoam™, a multi-layer foam dressing that combines Hydrofiber® with superabsorber fibers and a gentle silicone adhesive. It is designed for superior exudate management and longer wear times, reducing the frequency of painful and costly dressing changes.

Convatec is also integrating its core technology with other treatment modalities. The ConvaVAC™ system is the first Negative Pressure Wound Therapy (NPWT) device to be partnered directly with an Aquacel® Hydrofiber® wound contact layer. This combination aims to control the wound's bioburden through bacterial sequestration while simultaneously delivering the negative pressure known to promote tissue granulation and healing.

“The challenges facing wound care require more than incremental change,” said Tanja Dormels, President of Advanced Wound Care at Convatec, in a statement ahead of the conference. Her comments capture the company's strategic focus on driving significant, evidence-led advancements to meet the needs of both patients and clinicians.

High Stakes in a Multi-Billion Dollar Market

The scale of Convatec's presentation at EWMA is a direct reflection of the enormous and growing market for advanced wound care. The global market was valued at over $11.7 billion in 2025 and is projected to surge to nearly $18 billion by 2033, fueled by an aging global population and the escalating prevalence of diabetes and other chronic conditions.

The specific segments targeted by Convatec's new products are particularly challenging and costly. The market for treating diabetic foot ulcers, a condition that can lead to amputation, was estimated at over $9.6 billion in 2025. Similarly, the market for treating venous leg ulcers is projected to exceed $4.8 billion by this year.

In this high-stakes environment, Convatec faces stiff competition from other industry giants like Smith & Nephew, Mölnlycke Health Care, and 3M. The company's aggressive R&D investment and its prominent, data-heavy presentation in Bremen represent a clear strategic maneuver to solidify its leadership position and capture a larger share of this lucrative market. The emphasis on randomized controlled trials and real-world evidence is designed to convince not just clinicians, but also hospital administrators and healthcare payers of the clinical and economic value of its new portfolio.

As the sessions at EWMA 2026 unfold, the healthcare community will be watching closely. The technologies being showcased promise not just better dressings, but a fundamental rethinking of how to manage wounds that have long resisted treatment. For the millions of people living with the daily pain and risk of chronic wounds, this innovation offensive could mean the difference between a life of suffering and a future of healing.